still very hungry on semaglutide Why am I Ozempic? Why Do I Still Feel

Key highlights: Once-daily oral administration Up to 11.8% weight loss over 36 weeks Focus on broader cardiometabolic health outcomes Advancement into Phase III development As obesity remains one of the most significant global health challenges, innovation in oral GLP-1 therapies could help improve accessibility and patient adherence while expanding treatment options beyond injectable therapies

Functional medicine and hormone clinic serving Olympia, WA

Reduce appetite & lose weight sustainably with medically guided semaglutide at Renew Health & Wellness

During the same period, obesity without T2DM notably increased from 10 to 31%